J&J, Zymeworks Partner for Bispecific Antibodies in $1-Billion-Plus Deal
By
Janssen Biotech, one of the pharmaceutical companies of Johnson & Johnson, has signed a license agreement worth up to $1.4 billion with Zymeworks, a Vancouver, Canada-headquartered clinical-stage biopharmaceutical company. Under…
Sanofi, Principia Biopharma in MS, CNS Drug Pact Worth up to $805 Million
By
Sanofi has partnered with Principia Biopharma, a South San Francisco, California-based clinical-stage biopharmaceutical company, to develop an experimental oral treatment for multiple sclerosis (MS) and other potential treatments for central…
FDA Commissioner Outlines Ways to Improve the Generic-Drug Review Process
By
US Food and Drug Administration Commissioner Scott Gottlieb has outlined the agency’s approach to increasing generic-drug competition by prioritizing generic drug reviews and addressing potential misuse of the Risk Evaluation…